Test LivPhcD capsules for fatty liver disease safety
Part of Digestive system clinical trials.
This trial studies whether LivPhcD capsules can improve fatty liver disease and checks for side effects. It may help people with non-alcohol-related fatty liver disease who meet specific liver-scanning and lab results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 20 to 75 and able to sign consent and communicate with the study team
- Have a BMI between 20 and 50 and stable weight for the past 3 months
- Have non-alcohol-related fatty liver confirmed by FibroScan showing F0 to F3 scarring level
- Have specific ultrasound-style FibroScan results (CAP ≥ 238 db/m)
- Not be pregnant or breastfeeding, and be willing to use effective birth control during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows adults with nonalcohol-related fatty liver disease (NAFLD) to better understand the condition and what factors affect it. It may help researchers learn which patients are most at risk and how care can be improved in the future.
This trial tests whether taking probiotics plus making lifestyle changes can improve fatty liver and metabolic health. You may qualify if you have liver fat and at least one sign of metabolic problems like high blood sugar or high blood pressure.
This study tests whether a specially designed gut bacteria treatment can help people with fatty liver disease and related health issues like high blood sugar, high cholesterol, or high blood pressure. It aims to see if the treatment is safe and improves liver health.
This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
This trial tests a new drug called HP515 for people with non-alcoholic fatty liver disease, including NASH or MASH. It aims to see if the drug can help reduce liver fat and improve liver health.
Hear when a new NAFLD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.